Atossa Therapeutics Inc (ATOS) Stock Price, Quote & News

Company Profile

Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa...

Industry: Biotechnology

Sector: Healthcare

Phone: 206 588 0256

Fax: 206 902 9658

Website: www.atossatherapeutics.com

Address:

107 Spring Street, Seattle, United States

Chalutz Dec. 7 at 9:31 AM

$ATOS To all bears . Thanks for your concern but like you I’m buying not selling. Take Weekends off it must be exhausting. DYOR and MYODS. GLTA!!!!

1 · Reply

Warrens__Buffet_ Dec. 7 at 12:25 AM

$ATOS looked at this further… seems very fishy. The lady on LinkedIn is clearly promoting the product more so in a way as a patient, but sounds like an investor. They are comparing it to tamox and making a strong nudge towards FDA approval. To me, the focus would be more on her personal journey, not a focus on endox and its product getting across the finish line. I have a nose for this stuff - seems artificial especially when looking through her history of commenting on ATOS LinkedIn page and being excited about data drops and other news. I smell investor hiding behind a guise of a woman with cancer.

0 · Reply

The_Profit_Prophet28 Dec. 6 at 6:11 PM

$ATOS I have a genuine question guys.. hear me out it’s literally all speculation. So a month ish ago we were all counting down the 10 days to regain compliance. We hit the 10 but the 20 day discretion was put into effect. That compliance wasn’t hit with any significant news other than “conversations, meetings, positive studies” blah blah. So it’s clear that there was some kind of buying whether from shareholders or the hedges, more likely the hedges due to the fact we would have about a million volume by 1030am. What’s to stop that from happening again?

3 · Reply

Bunster Dec. 6 at 6:09 PM

$ATOS when is my friend in&out coming back in and BEING BULLISH? I have never seen a stock message board with more AMNESIA then this one.LOL.LONGS, ITS OK IF U R NOT BULLSIH WITH THIS POS.u wont be blocked by all the other bulls. oh wait on this mb maybe u will be. prime

1 · Reply

_level_m_ Dec. 6 at 5:47 PM

$ATOS

1 · Reply

Warrens__Buffet_ Dec. 6 at 5:12 PM

$ATOS fake post I can’t find any history from that person on X looks like a desperate bull staged this

0 · Reply

nml7 Dec. 6 at 5:50 AM

$ATOS still confused on the new rules, would we have to stay above a buck for 20 days consecutively now or just need 10 more additional days to the 10 that they already did which should have gotten us compliance to begin with?

2 · Reply

Kittyc803 Dec. 6 at 4:40 AM

$ATOS

0 · Reply

Kittyc803 Dec. 6 at 3:54 AM

$ATOS @idunno123 Ty phil . Best post of the week . Wow 😮 Lilly is the key 🔑 🙏

2 · Reply

Bunster Dec. 6 at 3:12 AM

$ATOS KNOW WHO MAYBE THE WRONGEST POSTER IN THE HISTORY OF STOCKTWITS... OUR GERRY

0 · Reply

Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum

Dec 2, 2025, 8:00 AM EST - 5 days ago

Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma

Nov 17, 2025, 9:07 AM EST - 20 days ago

Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation

Nov 12, 2025, 8:15 AM EST - 25 days ago

Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Nov 6, 2025, 8:00 AM EST - 4 weeks ago

Atossa Therapeutics Announces Acceptance of Four Abstracts Highlighting (Z)-Endoxifen Research for Presentation at the 2025 San Antonio Breast Cancer Symposium

Oct 21, 2025, 8:00 AM EDT - 6 weeks ago

Atossa Therapeutics Highlights Progress in RECAST™ DCIS Platform Trial at Early Detection Research Conference; Laura Esserman, MD, MBA, to Discuss Active-Surveillance Strategy and Novel Endocrine Agents

Oct 15, 2025, 8:00 AM EDT - 7 weeks ago

Atossa Therapeutics to Present at the Maxim Growth Summit 2025

Oct 14, 2025, 8:00 AM EDT - 7 weeks ago

Atossa Appoints Mark Daniel, CPA, as Chief Financial Officer to Lead Finance, Systems, and Capital Strategy for Commercial Readiness

Oct 13, 2025, 8:00 AM EDT - 7 weeks ago

Atossa Advances Global Patent Strategy for Z-Endoxifen with New Protection in Israel and Ongoing Renewals

Oct 6, 2025, 8:00 AM EDT - 2 months ago

Atossa Therapeutics Streamlines EVANGELINE Breast Cancer Clinical Trial to Prioritize for 2026 NDA-Enabling Activities

Oct 1, 2025, 8:30 AM EDT - 2 months ago

Atossa Therapeutics Names Janet R. Rea, MSPH, as Senior Vice President, R&D to Accelerate (Z)-Endoxifen Toward Key Regulatory Milestones

Sep 17, 2025, 8:00 AM EDT - 2 months ago

Atossa Therapeutics Appoints CORE IR for Investor Relations, Shareholder Communications and Public Relations Services

Sep 8, 2025, 8:30 AM EDT - 3 months ago

Atossa Therapeutics Announces Regulatory Strategy Aimed at Accelerating Development of Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction

Aug 28, 2025, 8:30 AM EDT - 3 months ago

Atossa Therapeutics CEO to Discuss Clinical Progress and Upcoming Milestones at 27th Annual H.C. Wainwright Global Investment Conference

Aug 20, 2025, 8:30 AM EDT - 3 months ago

Atossa Therapeutics Selects PSI as Contract Research Organization for Pivotal Dose-Ranging Study of (Z)-Endoxifen in Metastatic Breast Cancer

Aug 12, 2025, 8:30 AM EDT - 4 months ago

Atossa Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Corporate Update

Jul 29, 2025, 7:45 AM EDT - 4 months ago

Atossa Therapeutics Announces Positive FDA Feedback, Advances Toward IND for (Z)-Endoxifen Clinical Program in ER+/HER2- Metastatic Breast Cancer

Jun 2, 2025, 8:45 AM EDT - 6 months ago

Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference

May 20, 2025, 9:00 AM EDT - 7 months ago

Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22

May 14, 2025, 8:15 AM EDT - 7 months ago

Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen

May 13, 2025, 8:00 AM EDT - 7 months ago

Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update

Apr 30, 2025, 8:45 AM EDT - 7 months ago

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio

Apr 29, 2025, 8:45 AM EDT - 7 months ago

Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025

Apr 22, 2025, 8:45 AM EDT - 8 months ago

Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio

Apr 10, 2025, 8:00 AM EDT - 8 months ago

Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer

Mar 25, 2025, 10:05 AM EDT - 9 months ago

Atossa Therapeutics, Inc. (ATOS) Q4 2024 Earnings Call Transcript

Mar 25, 2025, 8:00 AM EDT - 9 months ago

Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update

Mar 20, 2025, 9:13 AM EDT - 9 months ago

Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Mar 11, 2025, 8:15 AM EDT - 9 months ago

Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications

Feb 5, 2025, 8:00 AM EST - 10 months ago

Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care

Jan 30, 2025, 8:17 AM EST - 11 months ago

Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No.

Jan 23, 2025, 8:15 AM EST - 11 months ago

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025

Dec 12, 2024, 8:15 AM EST - 1 year ago

Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium

Dec 11, 2024, 8:15 AM EST - 1 year ago

Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density

Dec 10, 2024, 9:05 AM EST - 1 year ago

Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium

Dec 9, 2024, 8:15 AM EST - 1 year ago

Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research

Nov 21, 2024, 8:30 AM EST - 1 year ago

Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research

Nov 20, 2024, 8:30 AM EST - 1 year ago

Atossa Therapeutics Announces Five Abstracts Highlighting (Z)-Endoxifen Research Accepted for Presentation at the 2024 San Antonio Breast Cancer Symposium

Nov 12, 2024, 8:30 AM EST - 1 year ago

Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 5, 2024, 8:30 AM EST - 1 year ago

Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development

Nov 4, 2024, 6:30 AM EST - 1 year ago

Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results:

Oct 31, 2024, 8:15 AM EDT - 1 year ago

Atossa Therapeutics Releases Promising Preliminary Analysis Demonstrating (Z)-Endoxifen's Potential to Rapidly Reduce Ki-67 and Tumor Volume in ER+/HER2- Breast Cancer

Oct 21, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer

Oct 14, 2024, 5:08 PM EDT - 1 year ago

Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit

Oct 1, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Commemorates Breast Cancer Awareness Month, Highlighting the Need for Innovation Across the Breast Cancer Treatment Continuum

Sep 10, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer

Sep 3, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 28, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Granted Additional Patent Protection for Endoxifen

Aug 21, 2024, 11:30 AM EDT - 1 year ago

Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer

Aug 20, 2024, 8:30 AM EDT - 1 year ago

Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations

Chalutz Dec. 7 at 9:31 AM

$ATOS To all bears . Thanks for your concern but like you I’m buying not selling. Take Weekends off it must be exhausting. DYOR and MYODS. GLTA!!!!

1 · Reply

Warrens__Buffet_ Dec. 7 at 12:25 AM

0 · Reply

The_Profit_Prophet28 Dec. 6 at 6:11 PM

3 · Reply

Bunster Dec. 6 at 6:09 PM

1 · Reply

_level_m_ Dec. 6 at 5:47 PM

$ATOS

1 · Reply

Warrens__Buffet_ Dec. 6 at 5:12 PM

$ATOS fake post I can’t find any history from that person on X looks like a desperate bull staged this

0 · Reply

nml7 Dec. 6 at 5:50 AM

2 · Reply

Kittyc803 Dec. 6 at 4:40 AM

$ATOS

0 · Reply

Kittyc803 Dec. 6 at 3:54 AM

$ATOS @idunno123 Ty phil . Best post of the week . Wow 😮 Lilly is the key 🔑 🙏

2 · Reply

Bunster Dec. 6 at 3:12 AM

$ATOS KNOW WHO MAYBE THE WRONGEST POSTER IN THE HISTORY OF STOCKTWITS... OUR GERRY

0 · Reply

idunno123 Dec. 6 at 2:28 AM

$ATOS https://www.linkedin.com/feed/update/urn:li:activity:7402447643962232832

1 · Reply

JDAAT Dec. 6 at 1:42 AM

$ATOS we will be in compliance by January 2026 no need to worry about these guys just wants your share cheaply that’s why they cry all day long

1 · Reply

Kittyc803 Dec. 6 at 12:34 AM

$ATOS Have a great weekend. I think we are about to see the true power of the tutes in the next couple of weeks . Hope i’m right 🙏 Get us there Doc 😆😆😆

4 · Reply

Bunster Dec. 5 at 11:34 PM

$ATOS week in review. pps dec 5 2025 78c quay puts out a fluff pr and vague about meeting results stock goes back under 70c for part of a day and rebounds to 79c.ROCKET BOY WINS THE AWARD FOR THE PERSON WHO SPENDS THE MOST TIME OUT OF HIS LIFE WATCHING THE ATOS TICKER.thats sad folks.

1 · Reply

Warrens__Buffet_ Dec. 5 at 11:04 PM

$ATOS tell me you’re an idiot without telling me. They have until Feb 2026 to meet compliance or it’s R/S. Everyone knows this. If you can’t do basic research you should not be invested. You bulls get worse and worse.

0 · Reply

Bunster Dec. 5 at 10:56 PM

$ATOS talk about being uninformed and posting wrong info Wizard .WHERE U BEEN SINCE NOV 12.WRONG STOCK ROOK.

0 · Reply

wizard1863 Dec. 5 at 10:50 PM

$ATOS Don’t know why they would, they are in compliance until October of next year.

0 · Reply

NOYES Dec. 5 at 10:40 PM

$ATOS did they effect 20:1 rs?

2 · Reply

Warrens__Buffet_ Dec. 5 at 10:13 PM

$ATOS you keep singing the same song for last year… when will you learn.

1 · Reply

JDAAT Dec. 5 at 9:09 PM

$ATOS Good 3 days nicely climbing soon we will be over $1

0 · Reply

Warrens__Buffet_ Dec. 5 at 8:04 PM

$ATOS not happening… plus R/S is almost a guarantee in Feb. no way they stay above $1 for 20 days

1 · Reply

dcajic2 Dec. 5 at 7:21 PM

$ATOS Bullish???? This company will likely have a reverse split within the next two months. After a decade company is I still in phase 2. A year away from having any data on very small study and likely 2 to 3 years away from larger study. Larger study has only enrolled 50 people out of 300. Reverse split will destroy all shareholder value. It will be they end

0 · Reply

Market Cap	103.25M
Revenue (ttm)	0.00
Net Income (ttm)	-25.50M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	844,200
Avg Vol	936,382
Day's Range	N/A - N/A
Shares Out	129.17M
Stochastic %K	85%
Beta	0.95
Analysts	Strong Sell
Price Target	$5.69